Home › Funds › Boxer Capital Management, LLC › CBIO
Boxer Capital Management, LLC position in CBIO
CRESCENT BIOPHARMA INC. · Health Care
Boxer Capital Management, LLC reported holding 226,843 shares of CBIO (CRESCENT BIOPHARMA INC.) in its Q3 2026 13F filing — a position valued at US$3.3M, representing 0.29% of its reported portfolio and ranking #37 among its reported holdings. Boxer Capital Management, LLC has disclosed CBIO holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Boxer Capital Management, LLC's CBIO position evolved
Boxer Capital Management, LLC first disclosed a stake in CBIO in Q2 2025 at 453,686 shares (US$7.3M). The position peaked in Q1 2026 at 453,686 shares, worth US$8.3M. Across 6 filings, Boxer Capital Management, LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 226,843 shares valued at US$3.3M — a reduction of -226,843 shares quarter over quarter.. Notable position changes include a 50% trim in Q3 2026 (shares fell 7% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 453.69K | $7.32M | New |
| Q3 2025 | 453.69K | $5.39M | Hold |
| Q4 2025 | 453.69K | $5.38M | Hold |
| Q1 2026 | 453.69K | $8.33M | Hold |
| Q2 2026 | 453.69K | $8.17M | Hold |
| Q3 2026 | 226.84K | $3.31M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CBIO and 13F data
CBIO (CRESCENT BIOPHARMA INC.) is a Health Care company. 66 other funds we track also report a position in CBIO — the largest reported positions include Fairmount Funds Management LLC (US$52.5M), BVF INC/IL (US$45.1M), Vestal Point Capital, LP (US$43.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CBIO
- Fairmount Funds Management LLC 3.60M sh · $52.54M · Q3 2026
- BVF INC/IL 3.09M sh · $45.14M · Q3 2026
- Vestal Point Capital, LP 3.00M sh · $43.77M · Q3 2026
- Venrock Adviser, LLC 2.13M sh · $31.13M · Q3 2026
- FCPM III SERVICES B.V. 2.02M sh · $29.51M · Q3 2026
- Opaleye Management Inc. 1.32M sh · $23.75M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 1.16M sh · $16.92M · Q3 2026
- Logos Global Management LP 850.00K sh · $12.40M · Q3 2026
- NEXTBio Capital Management LP 372.86K sh · $5.44M · Q3 2026
- Remedium Capital Partners, LLC 361.25K sh · $5.27M · Q3 2026
- Squadron Capital Management LLC 350.00K sh · $5.11M · Q3 2026
- SPHERA FUNDS MANAGEMENT LTD. 279.72K sh · $4.08M · Q3 2026
More on Boxer Capital Management, LLC
FAQ
How long has Boxer Capital Management, LLC held CBIO?
Boxer Capital Management, LLC has disclosed CBIO holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
What is Boxer Capital Management, LLC's current position in CBIO?
As of Q3 2026, Boxer Capital Management, LLC holds 226.84K shares of CBIO (CRESCENT BIOPHARMA INC.), valued at $3.31M, representing 0.29% of its reported portfolio and ranking #37.
Has Boxer Capital Management, LLC been buying or selling CBIO?
In the latest 13F filing (Q3 2026), Boxer Capital Management, LLC reduced its position in CBIO. The position peaked in Q1 2026 at 453.69K shares.
Which other funds hold CBIO?
Other major institutional holders of CBIO include Fairmount Funds Management LLC, BVF INC/IL, Vestal Point Capital, LP, among 66 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.